NeuroXess (Shanghai NeuroXess Technology) is a life science company founded in 2021 that develops implantable flexible brain-computer interfaces (BCIs), with full-chain in-house R&D from core chips to algorithms. Its flagship Triple-F system — fully implanted, fully wireless and fully functional — pairs flexible electrodes placed beneath the dura mater with the XessOS BCI operating system to restore motor and language function for patients with ALS, paralysis and stroke; in July 2026 it became the first Chinese BCI system to enter Class III medical device registration clinical trials, led by Huashan Hospital with nearly 20 tertiary hospitals participating. The company runs a mass-production super factory and is developing BCI+AI integration for next-generation human-machine interaction.
1
Round
1
Industry
5
Tags
Oct 28, 2026
Latest raise
Funding activity · 1 round
Oct 28, 2026
CNY 700M
Series B
Led by SDIC Unity Capital
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
